ELDRED KARY 4

What Happened

Eldred Kary, a director of Galectin Therapeutics, was granted 60,000 derivative securities (stock options) on January 16, 2026. The Form 4 lists the acquisition price as $0 (derivative transaction type "A" — award/grant). This was a grant of options, not a purchase or sale, so no cash changed hands at the time of the filing.

Key Details

• Transaction date: 2026-01-16 (grant of 60,000 options)
• Reported acquisition price/value on Form 4: $0 (derivative)
• Filing date: 2026-01-21 (filed 5 days after the transaction) — appears late relative to the usual 2-business-day Form 4 reporting requirement
• Shares owned after transaction: not specified in the filing
• Footnotes:
  • F1: Options issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
  • F2: Options vest 100% on December 31, 2026.

Context

This was an equity-compensation grant (stock options) rather than an exercise or market trade; the options were not sold or exercised at grant. Vesting is full and occurs on December 31, 2026, meaning the options likely won’t be exercisable until that date (subject to plan terms). Grants like this are routine director compensation and don't by themselves signal immediate buying or selling intent. The multi-day delay in filing reduces timely transparency but does not by itself indicate any specific impropriety.